Generics

Filter

Current filters:

None

Popular Filters

76 to 100 of 1240 results

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

14-05-2014

US generic drugmaker Mylan says it has launched Olanzapine Orally Disintegrating tablets (ODT), 5mg,…

ActavisEli LillyExalgoGenericsMallinckrodtMarkets & MarketingMylanNeurologicalRegulationUSAZyprexa

Fresenius Kabi expands IV drug business in Latin America with buy of Novafarma

Fresenius Kabi expands IV drug business in Latin America with buy of Novafarma

13-05-2014

Germany-based Fresenius Kabi has entered into an agreement to acquire the privately held Brazilian pharmaceutical…

BrazilFresenius KabiGenericsMergers & AcquisitionsNovafarma Industria Farmaceutica

Akorn to acquire VersaPharm for $440 million

Akorn to acquire VersaPharm for $440 million

10-05-2014

Following swiftly on its completion of the acquisition of Hi-Tech Pharmacal (Nasdaq: HITK) for $640 million…

AkornDermatologicalsGenericsMergers & AcquisitionsVersaPharm

Vivus says Actavis has filed ANDA for generic Qsymia

Vivus says Actavis has filed ANDA for generic Qsymia

10-05-2014

US drug developer Vivus disclosed on Friday that the company had received notice from generics major…

ActavisGenericsMetabolicsPatentsQsymiaRegulationUSAVivus

Actavis debuts generic copy of Catapres-TTS

Actavis debuts generic copy of Catapres-TTS

08-05-2014

Ireland-headquartered generics major Actavis has launched a generic version of German family-owned pharma…

ActavisBoehringer IngelheimCardio-vascularCatapres-TTSGenericsMarkets & MarketingUSA

Grunenthal strengthens pain product portfolio with European rights to etoricoxib

07-05-2014

Family-owned German drugmaker Grunenthal Group today announced the signing of an exclusive promotion…

etoricoxibEuropeGenericsGrunenthalLicensingMerck & CoNeurological

Australian Audit Commission’s “nuclear option to attack the PBS is madness”

Australian Audit Commission’s “nuclear option to attack the PBS is madness”

05-05-2014

The Australian National Commission of Audit’s complete dismantling and destruction of the Pharmaceutical…

AustraliaFinancialGenericsHealthcarePolitics

Sun Pharma vows “appropriate action” as Ranbaxy merger halted

05-05-2014

In the wake of a suspension of its proposed $4 billion acquisition of domestic rival Ranbaxy Laboratories…

GenericsIndiaMergers & AcquisitionsProductionRanbaxy LaboratoriesSun Pharmaceutical IndustriesUSA

FTC Amicus Brief urges Court of Appeals to reverse DC ‘No-Authorized Generic’ commitments ruling

03-05-2014

The US Federal Trade Commission filed an Amicus Brief in the US Court of Appeals for the Third Circuit,…

ActavisGenericsLamictalLegalPatentsUSA

Teva 1st-qtr 2014 boosted by new generics

Teva 1st-qtr 2014 boosted by new generics

01-05-2014

Israel generic giant Teva Pharmaceutical Industries reported a 2% rise in revenues to $5.0 billion for…

FinancialGenericsTeva Pharmaceutical Industries

Mylan 1st-qtr 2014 revenues miss analysts’ expectations

Mylan 1st-qtr 2014 revenues miss analysts’ expectations

01-05-2014

US generic drugmaker Mylan reported first-quarter 2014 results before markets opened, posting adjusted…

FinancialGenericsMylan

Actavis swings into profit as 1st-qtr 2014 sales leap 40%

Actavis swings into profit as 1st-qtr 2014 sales leap 40%

30-04-2014

Ireland headquartered generics giant Actavis saw its shares rise 2.6% to $203 in mid-morning trading,…

ActavisFinancialGenerics

EU approval for Teva’s DuoResp Spiromax for asthma and COPD

EU approval for Teva’s DuoResp Spiromax for asthma and COPD

30-04-2014

The European Commission has granted marketing authorization for Israel-based Teva Pharmaceutical Industries’…

DuoResp SpiromaxEuropeGenericsRegulationRespiratory and PulmonaryTeva Pharmaceutical Industries

Endo to buy Mexican specialty pharma company Somar

29-04-2014

USA-based Endo International as entered into a definitive agreement to acquire Grupo Farmaceutico Somar,…

Endo PharmaceuticalsGenericsMergers & AcquisitionsMexicoSouth America

Mylan challenges FDA ruling on exclusivity relating to generic celecoxib

Mylan challenges FDA ruling on exclusivity relating to generic celecoxib

27-04-2014

US generics firm Mylan has filed suit against the US Food and Drug Administration, challenging the agency's…

CelebrexGenericsInflammatory diseasesLegalMylanPatentsPfizer

Actavis settles Celebrex patent challenge with Pfizer

24-04-2014

Ireland-headquartered generic major Actavis has entered into an agreement with US pharma giant Pfizer…

ActavisAnti-Arthritics/RheumaticsCelebrexGenericsLegalPatentsPfizerUSA

Abbott may acquire one of Russia’s leading drugmakers for $240 million

23-04-2014

The USA’s Abbott Laboratories is considering acquiring the 81.1 % stake in Veropharm, one of Russia’s…

Abbott LaboratoriesGenericsMergers & AcquisitionsRussiaVeropharm

Teva and Pfizer settle patent litigation over Celebrex

17-04-2014

Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

76 to 100 of 1240 results

Back to top